相关实验视频
Updated: Aug 9, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
抑制KCTD20可以减轻病患者器官中的兴奋毒性
Joshua E Berlind1, Jesse D Lai2, Cecilia Lie1
1Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, CA, USA.
谷氨酸兴奋毒性驱动神经退行性疾病中的tau病理. 抑制KCTD20激活 lysosomal exocytosis以清除有毒的tau,提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 兴奋毒性是陶病和神经退行性疾病的关键因素.
- 神经毒性的主要驱动因素和有效的缓解策略仍然不清楚.
研究的目的:
- 调查谷氨酸在诱导病理中的作用.
- 确定治疗目标,以减轻与相关的神经退行.
主要方法:
- 使用诱导多能干细胞 (iPSC) 衍生的大脑器官.
- 进行了全基因组的CRISPR干扰 (CRISPRi) 屏幕.
- 在有机体和小鼠模型中测试了KCTD20抑制.
主要成果:
- 谷氨酸治疗在有机体中诱导的寡合化和神经退行,在患者衍生的有机体中恶化.
- 抑制KCTD20显著降低了tau病理和神经退行.
- 抑制KCTD20增强了 lysosomal exocytosis,清除了病态tau,并改善了神经元的存活率.
结论:
- 谷氨酸信号传递可以启动神经元病理.
- 抑制KCTD20是一种可行的策略,可以清除神经毒性tau物种.
- 激活 lysosomal exocytosis 提供了一种治疗方法来治疗病.
相关概念视频
Inhibition of CDK Activity
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Acting on Autonomic Ganglia: Blockers
Drugs Affecting Neurotransmitter Release or Uptake
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

